Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (1314)	5/8/2002 12:59:29 PM
From: Micawber	Respond to of 1475

Looks to me like the market is expecting the dilution. This has been a really sad, frustrating story. Eligix sellers must have known what they were doing. Is survival really the issue at this point?

To: tuck who wrote (1314)	5/9/2002 7:52:35 AM
From: jayhawk969	Read Replies (1) \| Respond to of 1475

This is a responsible decision. Any good news from MEDI or an upturn in Eligix and they will have an opportunity to raise cash. Dilution at this point is a serious issue. However, I think Lebowitz is smart and will look at his options and find a way to stretch this one out. Something in this program will click. The market cap is down to $63MM.

To: tuck who wrote (1314)	5/13/2002 8:33:53 AM
From: Arthur Radley	Read Replies (1) \| Respond to of 1475

Q report out and revs were about $500,000...but cash burn is $4.1M....Positive comments about clinical trials....BUT! We need news of the actual start of the phase II trials for PA.

To: tuck who wrote (1314)	6/12/2002 9:01:11 PM
From: smh	Read Replies (2) \| Respond to of 1475

>>CHARLESTOWN, Mass.--(BUSINESS WIRE)--May 8, 2002--BioTransplant (Nasdaq: BTRN - news) today announced a cost reduction program in order to advance the Company's product lines while streamlining operations and reducing overall costs. This program includes a reduction in workforce and spending cuts impacting all segments of the Company. "These cost reduction measures are expected to conserve the needed resources to continue developing BioTransplant's promising product lines," commented Dr. Elliot Lebowitz, CEO of BioTransplant. With these spending adjustments, BioTransplant expects to have operating capital for approximately three to four fiscal quarters. << That was just one month ago. What was the point? I assumed he was trying to buy time - waiting for a better opportunity - presumably following some overdue good news. Does this mean there will be no good news? I don't see how the timing of the last two stock giveaways could possibly have been worse. Disgusted